Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition

<p>Supplementary Table S2</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Yufang Bao (15386826) (author)
Altres autors:	Sirui Zhang (15386829) (author), Xiaoyu Zhang (15386832) (author), Yunjian Pan (15386835) (author), Yueren Yan (15386838) (author), Ning Wang (15386841) (author), Yunpeng Ren (15386844) (author), Ji Zuo (15386847) (author), Wei-Xing Zong (15386850) (author), Zefeng Wang (15386853) (author), Yongbo Wang (15386856) (author)
Publicat:	2025
Matèries:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Computational Methods Sequence analysis Drug Resistance Regulation of gene expression in drug resistance Reversal of drug resistance Gene Regulation Posttranscriptional and translational control Lung Cancer Oncogenes & Tumor Suppressors Tumor suppressor genes Preclinical Models Animal models of cancer
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
per: Yufang Bao (15386826)
Publicat: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
per: Yufang Bao (15386826)
Publicat: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
per: Yufang Bao (15386826)
Publicat: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
per: Yufang Bao (15386826)
Publicat: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
per: Alex C.H. Liu (14961921)
Publicat: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
per: Alex C.H. Liu (14961921)
Publicat: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
per: Alex C.H. Liu (14961921)
Publicat: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
per: Alex C.H. Liu (14961921)
Publicat: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
per: Alex C.H. Liu (14961921)
Publicat: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
per: Alex C.H. Liu (14961921)
Publicat: (2025)

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
per: Yun-Guang Hong (14960966)
Publicat: (2025)

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
per: Yun-Guang Hong (14960966)
Publicat: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
per: Yun-Guang Hong (14960966)
Publicat: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
per: Yun-Guang Hong (14960966)
Publicat: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
per: Yun-Guang Hong (14960966)
Publicat: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
per: Yun-Guang Hong (14960966)
Publicat: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
per: Jiachun Su (16990970)
Publicat: (2025)

Supplementary File 2 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
per: Charles Blatti (15292859)
Publicat: (2025)

Supplementary File 3 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
per: Charles Blatti (15292859)
Publicat: (2025)

Supplementary File 4 from Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
per: Charles Blatti (15292859)
Publicat: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Supplementary Data S1 from A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States
per: Namhee Kim (14963603)
Publicat: (2025)

Supplementary Data S2 from A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States
per: Namhee Kim (14963603)
Publicat: (2025)

Supplementary Table 1 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
per: Duygu Kuzuoglu-Ozturk (14960213)
Publicat: (2025)

Supplementary Table 2 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
per: Duygu Kuzuoglu-Ozturk (14960213)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_6e6nuj4el1969mmb76tfeajfts